Hledání v detailu akcií
Top akcie
NázevNávštěvy
19 188
879
854
807
610
539
528
384
378
374
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN82,3654,8-0,36
Msft98,6998,7-1,70
Nokia4,9255-2,90
IBM139,43139,44-1,30
DCX56,2756,29-2,76
PFE36,336,31-0,55
25.6.2018 17:45:37
Indexy online
AD Index online
select
AD Index online
 

  • 25.6.2018 17:45:57
CymaBay (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
13,52 -1,60 -0,22 506 756
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 25.6.2018
Popis společnosti
Obecné informace
Název společnostiCymaBay Therapeutics Inc
TickerCBAY
Kmenové akcie:Ordinary Shares
RICCBAY.O
ISINUS23257D1037
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 26
Akcie v oběhu k 30.4.2018 58 768 799
Počet akcionářů k 31.12.2017 263
MěnaUSD
Kontaktní informace
Ulice7999 Gateway Blvd Ste 130
MěstoNEWARK
PSČ94560-1188
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 102 938 800
Fax15102939090

Business Summary: CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
Financial Summary: BRIEF: For the three months ended 31 March 2018, CymaBay Therapeutics Inc revenues decreased from $4.8M to $0K. Net loss increased from $5.4M to $17M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Develop increase from $3.7M to $8.8M (expense), Other (expense) income, Net increase from $2.1M to $4.7M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 25.6.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardRobert Wills628.10.20158.10.2015
President, Chief Executive OfficerSujal Shah421.11.20176.12.2013
Senior Vice President, Chief Scientific OfficerCharles McWherter62
Vice President - Finance, Principal Financial Officer, Principal Accounting OfficerDaniel Menold4727.4.201727.4.2017
Vice President - Regulatory Affairs and Quality AssuranceKirk Rosemark4427.4.201527.4.2015
General Counsel, Corporate SecretaryPaul Quinlan534.12.20174.12.2017
Chief Medical OfficerPol Boudes593.3.20143.3.2014